申请人:——
公开号:US20030181490A1
公开(公告)日:2003-09-25
The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula
1
wherein R
1
is C
1
-C
4
alkyl, carbocyclic radical, heterocyclic radical, aryl-C
1
-C
2
alkylene, aryloxy-C
1
-C
2
alkylene, alkoxy-CC(O)—, wherein R
1
is optionally substituted from 1-3 times with halo, C
1
-C
2
alkyl or C
1
-C
2
alkoxy, or R
1
is H; R
2
is H or C
1
-C
4
alkyl; R
3
is H, C
1
-C
4
alkyl or phenyl-C
0
-C
2
alkylene which is optionally substituted with 1-3 R
5
; R
4a
is carbocylic radical, heterocyclic radical, aryloxy, aryl-C
1
-C
4
alkylene, aryl-cyclopropylene, aryl-NHC(O)—, wherein R
4a
is optionally substituted with 1-3 R
5
; and wherein each R
5
is independently selected from H, halo, C
1
-C
4
alkyl, C
1
-C
4
alkenyl, C
1
-C
4
haloalkyl, C
1
-C
4
alkoxy, R
6
-phenyl, R
6
-phenoxy, R
6
-benzyl, R
6
-benzyloxy, NH
2
C (O)—, alkyl-NHC(O)—, wherein R
6
is H, halo; Z is a bond or a substituted or unsubstituted C
1
-C
4
alkylene group; and B
2
is
2
本发明涉及抑制HIV整合酶的化合物,并通过给予式1中的化合物治疗艾滋病或ARC,其中R1为C1-C4烷基,碳环基,杂环基,芳基-C1-C2烷基,芳氧基-C1-C2烷基,烷氧基-CC(O)-,其中R1可以用卤素,C1-C2烷基或C1-C2烷氧基从1-3次取代,或R1为H;R2为H或C1-C4烷基;R3为H,C1-C4烷基或苯基-C0-C2烷基,该苯基-C0-C2烷基可以选择性地用1-3个R5取代;R4a为碳环基,杂环基,芳氧基,芳基-C1-C4烷基,芳基环丙基,芳基-NHC(O)-,其中R4a可以选择性地用1-3个R5取代;每个R5都是独立选择的H,卤素,C1-C4烷基,C1-C4烯基,C1-C4卤代烷基,C1-C4烷氧基,R6-苯基,R6-苯氧基,R6-苄基,R6-苄氧基,NH2C(O)-,烷基-NHC(O)-,其中R6为H,卤素;Z为键或取代或未取代的C1-C4烷基;B2为2。